Tandem Diabetes Care Inc (TNDM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tandem Diabetes Care Inc (TNDM) Stock Forecast
Analysts expect Tandem Diabetes Care (TNDM) to earn -$0.60 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.08B. Of 25 analysts, 13 rate the stock Buy or Strong Buy, 12 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.13.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 25 ratings average 2.40, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 52% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 8.0% |
| Buy | 11 | 44.0% |
| Hold | 12 | 48.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 25
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 7.4%.
- Fiscal year ending Dec 31, 2026
- -$0.60
- EPS consensus, revenue $1.08B
- Fiscal year ending Dec 31, 2027
- $0.13
- EPS consensus, revenue $1.16B
- Next report
- Feb 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.60 | -$0.70 to -$0.49 | 19 | $1.08B | $1.06B to $1.09B | 24 |
| Dec 31, 2027 | $0.13 | -$0.19 to $0.57 | 18 | $1.16B | $1.12B to $1.20B | 24 |
Quarterly Estimates
The EPS consensus falls from $0.10 for the quarter ending Dec 31, 2026 to -$0.15 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.10 | -$0.01 to $0.22 | 26 | $297.39M | $273.91M to $315.11M | 25 |
| Mar 31, 2027 | -$0.15 | -$0.25 to $0.00 | 16 | $263.84M | $252.00M to $277.30M | 18 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.68.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.60 | -$0.66 | -$0.66 | -$0.67 | -$0.68 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.13 | $0.16 | $0.16 | $0.17 | $0.18 | -27.7% |
| Quarter ending Mar 31, 2027 | -$0.15 | -$0.11 | -$0.11 | -$0.11 | -$0.11 | N/A |
Frequently Asked Questions About TNDM
What is the TNDM stock forecast?
Consensus analyst estimates put Tandem Diabetes Care's EPS at -$0.60 for the fiscal year ending Dec 31, 2026, on revenue of $1.08B. The consensus rating from 25 analysts is Buy.
How do analysts rate TNDM stock?
Of 25 analysts covering Tandem Diabetes Care, 2 rate it Strong Buy, 11 Buy, 12 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TNDM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.60, with estimates from -$0.70 to -$0.49 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.13, with estimates from -$0.19 to $0.57 from 18 analysts.
What revenue do analysts expect from Tandem Diabetes Care next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.08B, with estimates from $1.06B to $1.09B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.16B, with estimates from $1.12B to $1.20B.
How many analysts cover TNDM?
25 analysts rate Tandem Diabetes Care stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TNDM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors